Hostname: page-component-586b7cd67f-l7hp2 Total loading time: 0 Render date: 2024-11-28T22:16:31.175Z Has data issue: false hasContentIssue false
  • English
  • Français

Use of Natalizumab in Multiple Sclerosis Patients

Published online by Cambridge University Press:  02 December 2014

Paul W. O'Connor
Paul W. O'Connor*
Affiliation:
Department of Neurology, St. Michael's Hospital, Toronto, ON, Canada
*
Department of Neurology, St. Michael’s Hospital, 30 Bond Street, Toronto, Ontario, M5B 1W8, Canada.
Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Article Commentary
Information
Canadian Journal of Neurological Sciences , Volume 37 , Issue 1 , January 2010 , pp. 98 - 104
Copyright
Copyright © The Canadian Journal of Neurological 2010

References

1. Polman, CH, O’Connor, PW, Havrdova, E, Hutchinson, M, Kappos, L, Miller, DH, et al. A randomized placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006 Mar 2;354:899–910.Google Scholar
2. Marrie, R. You get what you measure. Evaluating endpoints in MS clinical trials. Neurology. 2008 Aug 26;71:620–1.CrossRefGoogle ScholarPubMed
3. Koch-Henriksen, N. No shortcuts to outcome in MS clinical trials? Neurology. 2009 Feb 24;72:686–7.CrossRefGoogle ScholarPubMed
4. Langer-Gould, A, Atlas, SW, Green, AJ, Bollen, AW, Pelletier, D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med. 2005 Jul 28;353(4):375–81. Epub 2005 Jun 9.Google Scholar
5. Kleinschmidt-DeMasters, BK, Tyler, KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon-beta-1a for multiple sclerosis. N Engl J Med. 2005 Jul 28;353(4):369–74. Epub 2005 Jun 9.CrossRefGoogle ScholarPubMed
6. Van Assche, G, Van Ranst, M, Sciot, R, Dubois, B, Vermeire, S, Noman, M, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn’s disease. N Engl J Med. 2005 Jul 28;353(4):362–8. Epub 2005 Jun 9.CrossRefGoogle ScholarPubMed
7. Biogen-Idec Canada Inc. Tysabri (natalizumab) Product Monograph. January 9, 2009.Google Scholar
8. Gold, R, Jawad, A, Miller, DH, Henderson, DC, Fassas, A, Fierz, W, et al. Expert opinion: guidelines for the use of natalizumab in multiple sclerosis patients previously treated with immuno-modulating therapies. J Neuroimmunol. 2007 Jul;187: 156–8. Epub 2007 May 11.Google Scholar
9. Consortium of MS Centers. Consortium of MS Centers MRI protocol for the diagnosis and follow-up of MS. [cited 2009 May] Available from: http://www.mscare.org/cmsc/images/pdf/mriprotocol2009.pdf Google Scholar
10. Goodman, AD, Rossman, H, Bar-Or, A, Miller, A, Miller, DH, Schmierer, K, et al. for the GLANCE Investigators. GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study. Neurology. 2009 Mar 3;72(9):806–12.Google Scholar
11. Rudick, RA, Stuart, WH, Calabresi, PA, Confavreux, C, Galetta, SL, Radue, EW, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006 Mar 2;354:911–23.Google Scholar
12. O’Connor, PW, Goodman, A, Kappos, L, et al. Results of clinical and magnetic resonance imaging analyses following cessation of natalizumab dosing in patients with multiple sclerosis. Presented at the European Committee for Treatment and Research in Multiple Sclerosis Annual Congress, 29 September 2006; Madrid, Spain.Google Scholar
13. O’Connor, P, Goodman, A, Kappos, L, et al. Safety of natalizumab upon re-dosing: preliminary results from STRATA study. Presented at the European Committee for Treatment and Research in Multiple Sclerosis Annual Congress, 11-14 October, 2007; Prague, Czech Republic.Google Scholar
14. Vellinga, MM, Casteligns, JA, Barkhof, F, Uitdehaag, BM, Polman, CH. Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients. Neurology. 2008 Mar 25;70(13 Pt 2):1150–1. Epub 2007 Sep 13.Google Scholar
15. Kappos, L, Bates, D, Hartung, HP, Havrdova, E, Miller, D, Polman, CH, et al. Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurol. 2007 May;6:431–41.CrossRefGoogle ScholarPubMed
16. Khatri, BO, Man, S, Giovannoni, G, Koo, AP, Lee, JC, Tucky, B, et al. Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function. Neurology. 2009 Feb 3;72:402–9.Google Scholar
17. Panzara, MA, Baldinetti, F, Belcher, G, Bozic, C, Hyde, R, Kim, R, et al. Natalizumab utilization and safety in patients with relapsing MS: Updated results from TOUCH™ and TYGRIS. Poster presented at the European Committee for Treatment and Research in Multiple Sclerosis Annual Congress, 17-20 September 2008, Montreal, Canada (Poster P488).Google Scholar
18. Goodin, DS, Cohen, BA, O’Connor, P, Kappos, L, Stevens, JC.; Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Assessment: The use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review). Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2008 Sep 2;71:766–73.Google Scholar
19. Yousry, TA, Major, EO, Ryschkewitsch, C, Fahle, G, Fischer, S, Hou, J, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med. 2006 Mar 2;354(9):924–33.CrossRefGoogle ScholarPubMed